State Advocacy Choice at Risk: Restricting Access to Medications for Persons living with Mental Illness NAMI Mini-Smarts Advocacy Training Revised Winter.

Slides:



Advertisements
Similar presentations
Depression in adults with a chronic physical health problem
Advertisements

Treating Schizophrenia in Low And Middle Income (LAMI) Countries: Challenges and opportunities Treating Schizophrenia in Low And Middle Income (LAMI) Countries:
+ HEALTH INSURANCE: UNDERSTANDING YOUR COVERAGE Navigator Name Blank County Extension UGA Health Navigators.
NAMI Illinois. Don’t Get Anxious! Get Active! March 2015 From our friends at the Supportive Housing Providers Association Let’s talk...
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 35Seriously and Persistently Mentally Ill, Homeless, or Incarcerated Clients.
QI Initiatives for Psychotropic Use in Foster Youth in Maine Lindsey Tweed MD MPH Office of Child & Family Services; Maine DHHS
1 Marsha Frankel, LICSW Clinical Director of Senior Services-JF&CS Ruth Grabel, MPA Program Specialist and Coordinator, Massachusetts Partnership on Substance.
Psychotic Disorders and Skill Training. Basic information Schizophrenia and Other Psychotic Disorders Thought Disorders is another term Prevalence: about.5-1.5%;
Development and Implementation of a CIT Training Curriculum in a County Jail.
Module 4: Interaction of. Objectives To be aware of the possible reasons why dual diagnosis occurs To be aware of the specific effects of substances on.
Jill Dennison Regional Lead, Western Region Schizophrenia Society of Ontario Mental illness and Seniors.
1 Module 3 Understanding Mental Disorders, Treatment, and Recovery.
Drug Therapy.  Although the causes of schizophrenia are still largely unknown, treatment for it focuses on lessening the type one and type two symptoms.
State Advocacy Telling Your Story NAMI Mini-Smarts Advocacy Training Winter 2009.
Schizoaffective Disorder What is it? How does it affect the person diagnosed? How is it dealt with? What is it? How does it affect the person diagnosed?
Major Depressive Disorder Presenting Complaints
© 2005 National Mental Health Association The Medicare Drug Benefit: What Is It and What Does it Mean for Mental Health?
Severe and Persistent Mental Illness and Mothers A Mothers’ Mental Health Toolkit Project Learning Video with Dr. Joanne MacDonald Reproductive Mental.
Implementing NICE guidance
Mental Health and Substance Abuse Needs and Gaps FY
Impact of Restricting Access to Antipsychotic Medications Review of the Current Literature.
Mental Health and Substance Abuse Needs and Gaps FY 2013.
Medication Access Economics: Michigan Data and Implications Howard B. Fleeter, PhD Prepared for Michigan Partners in Crisis Annual Winter Conference December.
The Business Case for Bidirectional Integrated Care: Mental Health and Substance Use Services in Primary Care Settings and Primary Care Services in Specialty.
West Coast University NURS 204
Bridges of Hope Faith Communities and NAMI. Torrents of Mental Illness.
A Big Unknown : How to Use Data to Improve Policy and Quality Jeffery Thompson, M.D. Chief Medical Officer Washington State Medicaid Academy Health Washington.
Mood Disorders. Video – Out of the Shadows Handout with questions – –Descriptions –Contributing factors –Treatments –Your curiosity.
What Therapies Are Used to Treat Psychological Problems?
Ohio Justice Alliance for Community Corrections October 13, 2011.
Treatment for Adolescents With Depression Study (TADS)
1 Jan Eldred Karen W. Linkins Lisa Mangiante December 10, 2008.
DataBrief: Did you know… DataBrief Series ● February 2013 ● No. 36 Medicare Beneficiaries With Severe Mental Illness and Hospitalization Rates In 2010,
Bridges of Hope Bridges of Hope Faith Communities and NAMI.
The Impact of Medicare Part D on Dual Eligible Psychiatric Patients’ Medication Access and Continuity.
Public Employees Benefits Board February 18, 2003 DIS Forum Building Board Room 605 E. 11th Olympia, Washington.
1 Governor’s Office of Health Policy and Finance MaineCare Pharmacy Initiatives.
Getting Evidence Based Psychosocial Treatments into Practice – Schizophrenia David L. Shern, Ph.D De la Parte Florida Mental Health Institute University.
ADOLESCENTS IN CRISIS: WHEN TO ADMIT FOR SELF-HARM OR AGGRESSIVE BEHAVIOR Kristin Calvert.
Copyright © 2015 McGraw-Hill Education. All rights reserved. No reproduction or distribution without the prior written consent of McGraw-Hill Education.
10/28/20151 INVOLUNTARY TREATMENT IN THE 21 ST CENTURY MAKING THE RECOVERY MODEL REAL Honorable Milton L. Mack, Jr. Chief Judge Wayne County Probate Court.
Status Report on Development of a Medicaid Preferred Drug List Program Presentation to: The Medicaid Pharmacy & Therapeutics Committee Cynthia B. Jones.
Implementing NICE guidance 2011 NICE clinical guideline 113 Generalised anxiety disorder in adults.
BCCO PCT #4 PowerPoint AND Intermediate CIT Course TCOLE Course # 3841 Texas Commission On Law Enforcement Participant Handout UNIT FOUR.
1 IRIS Initiative to Reduce the Impact of Schizophrenia DON’T DELAY! IT’S TIME TO REDUCE THE IMPACT OF PSYCHOSIS IN YOUNG PEOPLE……. NOW!
Reaching out to Faith Communities Part I Laying the Foundation.
Mental Disorders & Resources for Help 7.MEH.3.1. Jacob Jacob is part of the local all-star baseball team. He just finished a long practice and decided.
Bridges of Hope Faith Communities and NAMI
Study Design & Population A retrospective cohort design was applied to the Medicaid administrative claims data of youth continuously enrolled in a Mid-Atlantic.
Reaching out to Faith Communities Part I Laying the Foundation 1.
Susan Gingerich, MSW A Brief Overview of First Episode Psychosis and A Description of the NAVIGATE Program Susan Gingerich, MSW
Schizoaffective, Delusional and Other Psychotic Disorders Chapter 17.
Children’s Policy Conference Keeping Kids Closer to Home Peter Selby, PhD -- February 24, 2016.
DANNA MAUCH, PHD PRESIDENT AND CEO MASSACHUSETTS ASSOCIATION FOR MENTAL HEALTH STATE POLICY ROUNDTABLE MASSACHUSETTS WOMEN IN GOVERNMENT (WIG) STATE HOUSE.
Disability Services.  Severe mental disorders that cause abnormal thinking and perceptions.  The two main symptoms include: delusions and hallucinations.
Medication Adherence and Substance Abuse Predict 18-Month Recidivism among Mental Health Jail Diversion Program Clients Elizabeth N. Burris 1, Evan M.
Measuring UNLV’s Health: Faculty and Staff Tell Us Their Story May 30, Annual Forum Association for Institutional Research San Diego, California.
An Orientation To Community Benefit: What Hospital Staff Need To Know.
WOMEN’S HEALTH ISSUES : WHAT YOU REALLY NEED TO KNOW ABOUT DEPRESSION AND SUICIDE.
PDCP – Leo Hayes High School. What is mental health? Stopping the Stigma Mental health and mental illness Specific mental illnesses Experience Finding.
Pao Balandra Ari Cacelín Alex Domínguez María Aguilar
State Strategies to Preserve Access to Mental Health Medications: A Conversation with Local Mental Health Leaders May
NAMI Smarts for Advocacy Medication: Protecting Choice
NAMI Smarts for Advocacy Advocacy Day: Changing Hearts & Minds
Youth at Disproportionate Risk for Substance Use: A look at Delaware Data Presented by The SEOW Funding for this project has been provided by the Department.
Chapter Eleven: Management of Chronic Illness
Developing an Effective Assisted Outpatient Treatment Program
NAMI Smarts for Advocacy Advocacy Day: Changing Hearts & Minds
Bipolar Disorder Bipolar Disorder Alex Dudash.
NAMI Iowa Day on the Hill Advocacy Training
Presentation transcript:

State Advocacy Choice at Risk: Restricting Access to Medications for Persons living with Mental Illness NAMI Mini-Smarts Advocacy Training Revised Winter 2009

State Advocacy 2 Choice at Risk In today’s budget-cutting environment, some states are proposing new restrictions on mental health medications in their Medicaid pharmacy programs

State Advocacy 3 Choice at Risk Why are some states proposing restrictions on medications? –Atypical antipsychotics and antidepressants are often a significant cost in Medicaid pharmacy budgets –Elected officials and Medicaid agencies may see potential for budget savings by restricting access However, officials and agencies often lack understanding of serious mental illness and mental health medications and may be unfamiliar with the unintended consequences

State Advocacy 4 To control costs, many states are erecting new barriers: –Limited choices of medications –(Higher) co-pays for non-preferred drugs –Limits on the number or type of covered prescriptions –Must “fail first” on a one medication before another is approved –Therapeutic substitution (getting a different medication at the pharmacy counter than the one prescribed)

State Advocacy 5 Choice at Risk What decision makers need to know: 1.Mental health medications are unique and play an important role in recovery 2.People who live with mental illness are vulnerable 3.The unintended consequences of restrictive access to mental health medications are unacceptable

State Advocacy 6 Mental Health Medications are Unique  Several different classes of medications are used to treat mental illnesses – stimulant and nonstimulant medications – anti-anxiety medications – mood stabilizers and anticonvulsants – antidepressants – antipsychotics  For many, mental health medications play an important role in recovery  Medication tolerance and continuation is often key to successful management of mental illness

State Advocacy 7 Mental Health Medications are Unique  Mental health medications—even those within the same class—often have biochemical differences that result in significant variation in side effects, drug interactions and effectiveness for every individual¹  Finding the most helpful and well-tolerated medications and doses can take multiple trials because effectiveness and side effects vary significantly for every individual

State Advocacy 8 Mental Health Medications are Unique “A medication that works well for one person with schizophrenia often doesn’t work well for another. Genetic variations are thought to play a key role in this difference in response. While patients search for the right medications, their illnesses may worsen.” The National Institute of Mental Health²

State Advocacy 9 Mental Health Medications are Unique  People with the same diagnosis may have different symptoms – The side effects of mental health medications are often used to treat symptoms (e.g. sedating or non-sedating)  Many individuals who live with mental illness have other co-occurring health conditions – Mental health medications have varying risks, so options are needed for individuals who have co-occurring disorders (e.g. heart disease or overweight)

State Advocacy 10 Mental Health Medications are Unique  While overall effectiveness of medications may be similar, the effectiveness for individuals varies greatly³ –About one in three with depression will improve after treatment with an SSRI antidepressant; others will get better with a different medication or by adding another medication. ⁴ –Intolerance or lack of efficacy with one SSRI antidepressant does not seem to predict the same with another. ⁵

State Advocacy 11 People Who Live with Mental Illness are Vulnerable  Medicaid enrollees are a vulnerable population—many have experienced failed treatment for mental illness  Individuals may experience significant functional impairment as a result of mental illness or co-occurring disorders – Impaired insight into treatment needs (due to disorganized thinking, paranoia, depression) – Challenges in navigating system barriers – Reduced social and financial support

State Advocacy 12 People Who Live with Mental Illness are Vulnerable  The CATIE study reported that nearly three-quarters of individuals in the trials stopped taking their antipsychotic medications. ⁶ – Due to the very nature of mental illness, a individual's willingness to take one medication or another may not be predictable. For this reason, open access is important in optimizing treatment adherence.

State Advocacy 13 The Unintended Consequences are Unacceptable  Failure to respond to or tolerate a mental health medication—or discontinuation— may lead to a devastating relapse  A psychotic, manic or depressive episode may result in lasting cognitive impairment, emergency department visits, hospitalization—even incarceration or suicide – One out of every five community hospital stays involves a principal or secondary diagnosis of mental illness ⁷ – About percent of jail and prison inmates and youth involved with juvenile justice have a serious mental illness ⁸, ⁹ –We lose one life to suicide every 15.8 minutes¹ ⁰

State Advocacy 14 The Unintended Consequences are Unacceptable  Restricting access to mental health medications has unintended consequences and high costs¹¹ –In a 2007 study of Medicare Part D recipients with mental illness, over one-half had problems accessing medications: 31% could not access needed medication refills 22% had medically necessary medications stopped or interrupted 18% had stable medication regiments changed –The consequences: 22% suffered an increase in suicidal thoughts or behaviors 20% required an emergency room visit 11% required hospitalization 3.1% became homeless

State Advocacy 15 The Unintended Consequences are Unacceptable  In 2003, Maine instituted a prior authorization and step therapy policy for atypical antipsychotics¹² – People affected by prior authorization requirements had a 29 percent greater risk of treatment discontinuity – Medication gaps and discontinuations are strong predictors of negative outcomes, like hospitalization and psychotic episodes – In March 2004, the policy was suspended citing adverse events

State Advocacy 16 The Unintended Consequences are Unacceptable  A ten-state study of Medicaid prescription drug policies revealed that use of preferred drug lists was associated with 5.4 times higher odds of medication access problems¹³ –Individuals with a medication access problem were 3.6 times more likely to suffer a significant adverse event such as hospitalization, incarceration or suicidal behavior –Prior authorization requirements were associated with 2.2 times greater likelihood of being reported homeless and 3.1 times greater likelihood of experiencing a psychiatric hospitalization –Preferred drug lists were associated with 1.8 times higher rates of emergency department visits and 2.3 times higher rates of hospitalization

State Advocacy 17 The Unintended Consequences are Unacceptable  Implementation of co-pays decreases use of needed medications and shifts costs – Medicaid co-payment policies decreased drug utilization by 17 percent; antipsychotic use by 15.2 percent 14 (fig. 1) – In the Oregon Health Plan, co-pays for prescriptions reduced pharmacy expenditures, but resulted in cost shifts (increased inpatient care), not cost savings 15 Implementation of Copay Policy

State Advocacy 18 Choice at Risk What decision makers need to know: 1.Mental health medications are unique and play an important role in recovery 2.People who live with mental illness are vulnerable 3.The unintended consequences of restrictive access to mental health medications are unacceptable

State Advocacy 19 Make it personal –Attend P&T Committee meetings –Visit your legislators –Talk with the media Broadcast your opinion –Online or paper petitions –Postcards to the Governor – s or letters to legislators –Blogs or letters to the editor –Videos on YouTube –Rallies Getting Your Message Across

State Advocacy 20 Delivering your message… One to three facts can make an impact Your personal story is powerful And remember, your story is always right. Your lived experience has value and meaning. Getting Your Message Across

State Advocacy 21 Decision makers are not therapists –Keep your story brief –Illustrate a point –Make a clear “ask” Tell Your Story Effectively

State Advocacy 22 Demo an Effective Story  Listen to the sample “Choice at Risk” story  Notice your reactions as you listen

State Advocacy 23 Deconstruct an Effective Story  Use your seven steps to telling your medication “Choice at Risk” story  Think about parts in the sample story that correspond to the seven steps

State Advocacy 24 Practice an Effective Story  Use your story practice sheet to write your own medication story  Refer to seven steps to telling your medication “Choice at Risk” story for help

State Advocacy 25 Introduce yourself Describe who you are, what you are advocating for and how you are affected by mental illness. Tell your story –What happened? –What helped? –How are you different today? Make your point and your “ask” Give a brief, positive message about the need for access to mental health medications to promote recovery Let your legislator or committee know the action or position you would like them to take Say thank you

State Advocacy 26 You can make a difference Commit to doing one act of advocacy in the next 72 hours Think about how you can make advocacy a regular part of your life “Act as if what you do makes a difference. It does.” –William James

State Advocacy 27 Resources